Pharmaceutical

Merck buys Mirus Bio to boost viral vector bioprocessing capacity

Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities.

Aug 3, 2024 - 04:00
Merck buys Mirus Bio to boost viral vector bioprocessing capacity
Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities.
Read the original article

Tags:

Previous Article

FDA expands GSK’s Jemperli approval for endometrial cancer

Next Article

AbbVie acquires Cerevel Therapeutics for $8.7bn

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘A safe place to fail’: ARPA-H chief on building a culture of risk-taking in science

‘A safe place to fail’: ARPA-H chief on building a cult...

Mar 20, 2023

CMO Moves: Regulatory catalysts for drug manufacturing – March 2023

CMO Moves: Regulatory catalysts for drug manufacturing ...

Mar 21, 2023

Incyte’s non-segmental vitiligo treatment approved in UK

Incyte’s non-segmental vitiligo treatment approved in UK

Jul 5, 2023